Literature DB >> 12171553

Non-peptide opioid receptor ligands - recent advances. Part I - agonists.

Agnieszka Kaczor1, Dariusz Matosiuk.   

Abstract

Developments in the domain of non-peptide opioid receptor agonists, beginning from the first evidence of opiate binding to definite receptors, are briefly summarized. The recent achievements are in a more detailed way depicted and discussed. Novel agonists for each of three opioid receptor basic types (delta, kappa and micro) are presented with the special emphasis on one-type-selective ligands. Such selective or even specific agonists have been synthesized with a moderate success. Considerably more serious difficulties concern searching for selective ligands for opioid receptor subtypes (micro(1), micro(2), delta(1), delta(2, kappasub>1), kappasub>2, kappasub>3) which may be connected with the fact that dissimiliarities observed in vivo result from postbinding processes (signaling). For the large number of opioid receptor ligands, their structural diversity and relative easiness of generating them from combinatorial libraries (not comparable even with that of orphanine receptors) it is justified to consider the plasticity of opioid receptors (micro-receptor especially). This remark, in conjunction with the existence of opioid receptor types and subtypes, may enable to create new drugs with significantly reduced side-effects. The above facts and brand new reports about highly-active opioid agonists possessing no moieties thought to be essential for agonist activity make the need of reevaluation of classical opioid receptor pharmacophore model extremely important. In general, research results suggest that selective agonists of opioid receptors can be found both in morphine type of ligands and new structures like pyrido-acridine derivatives (COMP1) or diphenylmethylpiperazine derivatives (SNC 80). Better understanding of the structural prerequisites of the opioid receptors binding domains will certainly lead to even more potent and more selective ligands in a near future.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12171553     DOI: 10.2174/0929867023369394

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  6 in total

1.  N-Alkyl-octahydroisoquinolin-1-one-8-carboxamides: a Novel Class of Selective, Nonbasic, Nitrogen-Containing κ-Opioid Receptor Ligands.

Authors:  Kevin J Frankowski; Partha Ghosh; Vincent Setola; Thuy B Tran; Bryan L Roth; Jeffrey Aubé
Journal:  ACS Med Chem Lett       Date:  2010-08-12       Impact factor: 4.345

2.  Design synthesis and structure-activity relationship of 5-substituted (tetrahydronaphthalen-2yl)methyl with N-phenyl-N-(piperidin-2-yl)propionamide derivatives as opioid ligands.

Authors:  Srinivas Deekonda; David Rankin; Peg Davis; Josephine Lai; Todd W Vanderah; Frank Porecca; Victor J Hruby
Journal:  Bioorg Med Chem       Date:  2015-11-23       Impact factor: 3.641

3.  Discovery of 5-substituted tetrahydronaphthalen-2yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands.

Authors:  Srinivas Deekonda; Lauren Wugalter; Vinod Kulkarni; David Rankin; Tally M Largent-Milnes; Peg Davis; Neemah M Bassirirad; Josephine Lai; Todd W Vanderah; Frank Porreca; Victor J Hruby
Journal:  Bioorg Med Chem       Date:  2015-08-04       Impact factor: 3.641

4.  Consensus 3D model of μ-opioid receptor ligand efficacy based on a quantitative Conformationally Sampled Pharmacophore.

Authors:  Jihyun Shim; Andrew Coop; Alexander D MacKerell
Journal:  J Phys Chem B       Date:  2011-05-12       Impact factor: 2.991

5.  Semisynthetic neoclerodanes as kappa opioid receptor probes.

Authors:  Kimberly M Lovell; Tamara Vasiljevik; Juan J Araya; Anthony Lozama; Katherine M Prevatt-Smith; Victor W Day; Christina M Dersch; Richard B Rothman; Eduardo R Butelman; Mary Jeanne Kreek; Thomas E Prisinzano
Journal:  Bioorg Med Chem       Date:  2012-03-01       Impact factor: 3.641

6.  Synthesis, central nervous system activity, and structure-activity relationship of 1-aryl-6-benzyl-7-hydroxy-2,3-dihydroimidazo[1,2-a]pyrimidine-5(1H)-ones.

Authors:  Marzena Rządkowska; Elżbieta Szacoń; Agnieszka A Kaczor; Sylwia Fidecka; Ewa Kędzierska; Dariusz Matosiuk
Journal:  Med Chem Res       Date:  2014-03-27       Impact factor: 1.965

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.